Announced ITF 4 August: Tan Delta Systems plc, a Sheffield based Company intends to IPO on AIM. Tan Delta has developed an innovative and differentiated monitoring solution based on real time oil analysis and analytics that offers equipment operators enhanced insight into the maintenance status of their equipment and thus the ability to reduce maintenance costs, improve reliability and reduce carbon footprint. Anticipated Market Cap £19m. Capital to be raised on Admission: £6.0m via primary proceeds and £0.57m via secondary sale of existing ordinary shares. Admission expected 18 August 2023.
Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market.
Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in the medical cannabis market by creating products that provide fast onset of action and accurate dosing, intends to join the Access Segment of the AQSE Growth Market. Admission delayed.
Fusion Antibodies 6.5p £4.0m (FAB.L)
The Contract Research Organisation providing discovery, design, and optimisation services for therapeutic antibodies to the healthcare market, announces an update on the Company's cost savings and restructuring plans, details of which were announced on 19 May 2023, at the time of the recent placing to raise approximately £1.67m. The Company has undertaken and completed a restructuring process set out at the time of the Placing to reduce annualised costs by approximately £2.2m and is on track to realise all the intended savings outlined. The Company continues to expend cash in a planned manner to grow the trading aspects of the business. As part of the cash saving measures, it is intended that certain directors of the Company will be issued new ordinary shares in Fusion in settlement of a portion of their salary. Further announcements will be made in due course, following the Company's annual report and accounts for the year.
Global Petroleum 0.16p £1.7m (GBP.L)
The Australia-based oil and gas, upstream exploration company announces that the Namibian Ministry of Mines and Energy has given approval for the Company and its partners to proceed to the First Renewal Period (FRP) of Walvis Basin licence PEL 94, with a duration of two years from September 2023 to September 2025. The work commitment for the FRP is to acquire, process and interpret 2,000 kms of 3D seismic data, carried over from the current Initial Exploration Period (IEP), and to drill a well contingent upon the results of interpretation of the 3D Seismic. The original well commitment for the FRP was firm, rather than contingent. The Ministry has waived the usual requirement to relinquish 50% of the licence area at the end of the IEP. This means that Global and its partners have retained all of the prospectivity of the licence on entry to the FRP, notably both of the primary prospects, Marula and Welwitschia Deep, together with the leads which the Company has identified in the eastern part of the licence.
Harvest Minerals 2.2p £4.2m (HMI.L)
The fertiliser producer, provides a trading update. Further to its Q2 sales update announced on 30 June 2023 when the Company noted a drop in fertiliser sales and prices, Harvest reports that sales for July remained below revised internal expectations. As at the end of July 2023, Harvest has recorded 36,000 tonnes of new sales orders for the period, this excludes the additional 33,000 tonnes of advanced sales that had been invoiced in 2022, but did not meet the definition of revenue in the year under accounting standards, so will be included in FY 2023 revenue. While the second half of the year is historically the Company's most active sales period, Harvest is observing that farmers are continuing to delay purchasing fertiliser until greater stability in the market is seen. The Company has revised again its 2023 invoiced sales target to 70,000 tonnes from 120,000 tonnes.
Insig AI 15.5p £16.1m (INSG.L)
The data science and machine learning solutions company and its subsidiaries announces its results for the year ended 31 March 2023. Revenue increased 22% year on year to £2.1m. The Group's legacy Sport in Schools business comprised £1.4m, with the core Insig AI business delivering an 85% increase in revenue to £0.7m. Loss for the year after income tax of £18.5m, which includes an impairment charge of £16.6m. The combined operating loss was £4.8m. Cash at bank as at 31 March 2023 was £0.3m. Following the year end, in April 2023, the Company raised £0.9m. The board remains optimistic that it will achieve operating profitability in FY24.
Jubilee Metals 7p £191.7m (JLP.L)
The metals processor with operations in Africa announces the expansion of its executive leadership team strategy with the appointment of Neal Reynolds as Chief Financial Officer (CFO) effective October 1, 2023, as well as Ricus Grimbeek who will be leading Jubilee’s expansion drive into energy metals with a specific focus on the roll-out of the Company’s Zambian Copper Strategy. Neal is a Chartered Accountant (South Africa) and holds more than 14 years of experience in mostly African focused mining and metals operations. He was most recently Chief Operational Officer at Chemaf, an established copper and cobalt producer in the Democratic Republic of the Congo. Pedja Kovacevic, the current acting CFO, will continue in his role as Chief of Strategy and Advisory. Ricus is a Mining Engineer and has more than 30 years of experience in the mining industry holding various executive management and technical roles with global mining houses.
Pelatro 3.25p £1.6m (PTRO.L)
The UK-based company providing telecom marketing software announces that it has raised £1.1m by way of a direct subscription in the Company with a number of new investors based in the Middle East. This funding will support the Company's working capital as it seeks to collect receivables as well as add new customers. The Issue Price of 2.5 pence per share represents a discount of 30% to the closing price on 11 August 2023. As announced on 18 July, the Group has been experiencing delays in collection of a number of significant receivables with a resulting impact on working capital, consequently the Board was exploring financing options to raise working capital.
Roquefort Therapeutics* 8.25p £10.7m (ROQ.L)
The biotech company focused on developing first in class medicines in the high value and high growth oncology market announces the successful filing of the international phase PCT (Patent Treaty Cooperation) patent for its proprietary anti-cancer mRNA and RNA oligonucleotide therapeutics. The announcement follows the development of the Company's novel anti-cancer RNA oligonucleotide and mRNA therapeutics targeting Midkine (MDK) announced on 13 and 22 June 2023, which are undergoing in vitro and in vivo studies. The studies demonstrated efficacy with the Company's MDK RNA Oligonucleotides and mRNA in validated in vitro models of breast and liver cancer. The MDK RNA oligonucleotide and mRNA programs have now progressed into combinations studies with a proprietary targeted nano-particle delivery technology and are scheduled to progress into in vivo studies in Q4 2023.
Serinus Energy 3.1p £3.4m (SENX.L)
The oil and gas exploration, appraisal and development company with assets in Romania and Tunisia announces its interim results for the six months ended 30 June 2023. Revenue decreased to $8.9m (30 June 2022: $29.3m) and gross profit was $0.8m (30 June 2022: $8.0m). EBITDA for the period was $0.5m (30 June 2022: $8.7m). The Company realised a net price of $74.93/boe for the six months ended 30 June 2023 comprising. Cash balance as at 30 June 2023 was $2.5m (31 December 2023: $4.9m).
Smarttech247 Group 31.5p £39.1m (S247.L)
The provider of AI-enhanced cybersecurity services providing automated managed detection and response announces the appointment of Sascha Maier to its Advisory Board. Sascha is currently the Group Chief Information and Security Officer at SV Group, a hospitality and catering group in Europe. Previously, Sascha held a number of positions across Europe, including 10 years as the Head of IT and Cyber Resilience at IWC Schaffhausen, Director of Cloud and Security Services at SwissCloud, and an IT Manager at DISA Industries. Additionally, Sascha is currently a member of the Advisory Board of the Swiss Cyber Institute.
ValiRx 7.15p £7.3m (VAL.L)
The life science company focusing on early-stage cancer therapeutics and women's health, announces that the Company’s wholly owned subsidiary, Inaphaea BioLabs Limited, has entered into a collaborative services agreement with Agility Life Sciences Limited. The Collaborative Services Agreement recognises the synergy between Inaphaea's growing capabilities as a translational contract research organisation (tCRO®) and Agility's capabilities for formulation development and optimisation, pre-formulation studies and analysis. Under the agreement, service users of Inaphaea will be able to benefit from Agility's capabilities in a single service contract with Inaphaea and similarly, service users of Agility will be able to access Inaphaea's capabilities through their service contract with Agility. This will enable a coherent, single point of contact for service users to formulate and test their drug candidates.
Disclaimer
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email enquiries@chrish351.sg-host.com with “unsubscribe me”.
